A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers

Completed

Conditions studied: Amyotrophic Lateral Sclerosis, Nervous System Diseases, Sclerosis, Motor Neuron Disease, Spinal Cord Diseases, Central Nervous System Diseases, Neurodegenerative Diseases, Neuromuscular Diseases, ALS

In brief

The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.

Key facts

Study ID

NCT01495390

Run by

Massachusetts General Hospital

People needed

139

Starts

2011-11-01

Expected to finish

2016-12-31

Last updated by the study team

2017-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Diagnosis of suspected, possible, probable or definite ALS according to El Escorial Criteria
• Vital capacity (VC) at least 50 percent predicted
• Able to undergo multiple lumbar punctures

You may not qualify if…

• Abnormal CSF pressure or intracranial/intraspinal tumors
• Use of anticoagulant medication that cannot be safely withheld
• Bleeding disorders
• This is a partial listing.

Where it is running

• Barrow Neurological Institute — Phoenix, Arizona, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Emory University — Atlanta, Georgia, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• University of Massachusetts Medical Center — Worcester, Massachusetts, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.